eXoZymes
eXoZymes is a pre-revenue, NASDAQ-listed biotechnology company that uses AI-engineered cell-free exozymes to sustainably biomanufacture rare natural compounds, serving pharmaceutical, nutraceutical, and specialty chemical markets through its Exozymes Platform and NCTx subsidiary.
- Company typePublic
- Founded2019
- HeadquartersMonrovia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What eXoZymes does
eXoZymes (NASDAQ: EXOZ) is a pre-revenue biotechnology company that has built an AI-enhanced, cell-free biomanufacturing platform for producing complex natural compounds that are rare, unscalable, or economically inaccessible through conventional means. The company's core technology centers on "exozymes" — enzymes engineered through AI and bioengineering to operate in bioreactors without living cells, eliminating the scaling bottleneck that has constrained traditional synthetic biology. The platform was demonstrated at 100-liter pilot scale in March 2026 with partner Cayman Chemical, producing 535 grams of pharma-grade NCT (N-trans-caffeoyltyramine) at 99.6% purity and 99% feedstock conversion efficiency, achieving a 100x scale-up from initial 1-liter lab work.
The company's product portfolio is organized around multiple commercialization paths from this shared technology core. Flagship product NCT is positioned for both over-the-counter metabolic wellness (through wholly-owned subsidiary NCTx, focused on gut and liver health) and pharmaceutical development of analogs targeting metabolic diseases. Additional pipeline assets include non-intoxicating cannabinoids for therapeutic applications and santalene for the fragrance market. Supporting technology includes the BioClick enzyme engineering platform backed by a $300K NIH grant. The company was founded in 2019 as Invizyne Technologies, completed its $15 million NASDAQ IPO in November 2024, rebranded to eXoZymes in February 2025, and is a portfolio company of MDB Capital Holdings with an estimated valuation of approximately $30 million as of Q4 2025.
The business model is built on technology licensing and royalty arrangements with pharmaceutical and nutraceutical companies, supplemented by contract manufacturing partnerships (e.g., Cayman Chemical) and direct commercialization through NCTx. Go-to-market is enterprise-focused, led by a Chief Commercial Officer appointed in April 2025, with distribution through direct partnerships and contract manufacturer networks. Revenue has not yet commenced; FY2025 financials show operating expenses of $9.72 million against a $9.16 million net loss, with cash reserves of $3.04 million at year-end 2025 replenished by a $5.95 million public offering in June 2026.
eXoZymes firmographics
Firmographics- Name
- eXoZymes
- Legal name
- eXoZymes Inc.
- Website
- https://exozymes.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- eXoZymes is a pre-revenue, NASDAQ-listed biotechnology company that uses AI-engineered cell-free exozymes to sustainably biomanufacture rare natural compounds, serving pharmaceutical, nutraceutical, and specialty chemical markets through its Exozymes Platform and NCTx subsidiary.
- Ownership category
- akta.pro rank
eXoZymes industry classification
Industry- Product category
- Cell-free Biomanufacturing
- NAICS
- Other Basic Organic Chemical Manufacturing (32519)
- SIC
- Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industry
- Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids) (IMAMALAB)
Keywords
Where eXoZymes is headquartered
LocationHeadquarters
- HQ city
- Monrovia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
eXoZymes business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Technology Licensing: Pre-revenue company with business model focused on licensing its cell-free biomanufacturing platform technology to pharmaceutical, nutraceutical, and specialty chemical companies. Revenue expected through technology licensing and royalty arrangements.
- Product Commercialization: Direct commercialization of high-value natural products including NCT (N-trans-caffeoyltyramine) and non-intoxicating cannabinoids. Company has launched subsidiary NCTx to commercialize NCT for gut and liver health applications.
- Contract Manufacturing Services: Potential revenue from providing biomanufacturing services using its platform, demonstrated through successful pilot runs with partner Cayman Chemical producing pharma-grade NCT.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
eXoZymes product offering
Product offeringCore offering
eXoZymes operates a proprietary cell-free biomanufacturing platform that uses engineered exozymes—cell-free enzyme systems designed with the aid of its AI-driven BioClick tool—to manufacture rare, high-value natural compounds at commercial scale. The company's first commercial focus is NCT (N-trans-caffeoyltyramine), a metabolic-health compound sold through its NCTx subsidiary, with a broader pipeline spanning non-intoxicating cannabinoids, santalene, and other specialty molecules for pharmaceutical, nutraceutical, and specialty-chemical buyers.
Product overview
eXoZymes is an AI-enhanced, cell-free biomanufacturing platform company (formerly Invizyne Technologies). The company offers a unified platform of exozymes (AI-engineered enzymes operating outside living cells) that transforms rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. The product portfolio centers on the core Exozymes Platform for cell-free biomanufacturing, with flagship product NCT (N-trans-caffeoyltyramine) offered in both over-the-counter wellness and pharmaceutical formulations, supported by the NCTx subsidiary. Additional products include non-intoxicating cannabinoids and santalene in the pipeline, plus the BioClick enzyme engineering technology. The platform collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths across pharmaceutical, wellness, and industrial markets.
Differentiator
Problem solved
Functional benefit
Brands
- NCTx: Subsidiary focused on gut and liver health products utilizing N-trans-caffeoyltyramine (NCT)
- NCT
- BioClick
Products and services
- Exozymes Biomanufacturing Platform The company's core cell-free biomanufacturing platform that uses engineered exozymes and the AI-driven BioClick design tool to produce rare, high-value natural compounds for pharmaceutical, nutraceutical, and specialty-chemical customers.
- NCT (N-trans-caffeoyltyramine) The company's flagship high-purity natural compound (N-trans-caffeoyltyramine) produced via the exozymes platform and positioned for metabolic-health applications, sold to nutraceutical and pharmaceutical customers.
- NCTx (Gut/Liver Health Brand) Specialty subsidiary brand through which eXoZymes markets NCT-based ingredients and formulations for gut-health and liver-health nutraceutical products.
- Non-intoxicating Cannabinoids (Pipeline) Pipeline of non-intoxicating cannabinoid molecules manufactured using the exozymes platform for pharmaceutical, wellness, and consumer-health buyers.
- Santalene (Pipeline) Cell-free produced santalene, a valuable natural aroma chemical traditionally constrained by sandalwood supply, targeted at fragrance and flavor customers.
- BioClick (Enzyme Engineering Platform) AI-enhanced enzyme engineering platform that designs and optimizes exozymes for the company's cell-free biomanufacturing processes, accelerating the design–build–test cycle for new biocatalysts.
Quantifiable outcome
- 99% feedstock conversion efficiency at 100-liter pilot scale
- +3 more outcomes
Companies that use eXoZymes
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
eXoZymes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
eXoZymes partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Shell GameChanger Accelerator Powered by NLR (GCxN)coreThree-year collaboration (2023-2026) with Shell and U.S. Department of Energy's National Laboratory of the Rockies. Program provided technical guidance and nondilutive funding to advance eXoZymes' cell-free biomanufacturing platform toward commercial viability. Collaboration helped evaluate separation approaches and conduct technoeconomic and lifecycle analysis modeling. Company graduated from the program in 2026.
- Cayman ChemicalcoreIndependent partner Cayman Chemical successfully validated eXoZymes' cell-free biomanufacturing technology at pilot scale, scaling from 1-liter to 100-liter production run. Produced over 500 grams of pharma-grade NCT at 99.6% purity with 99% feedstock conversion. This was the first end-to-end run of eXoZymes' exozyme-based biomanufacturing process by a third party, demonstrating protocol transferability and operational robustness.
- B2i DigitalminorPartnership with B2i Digital to spotlight the company's cell-free, AI-guided enzyme platform for scalable biomanufacturing. B2i Digital provides marketing and visibility services to highlight the company's technology and commercial opportunities.
- BioMADEcoreTwo senior eXoZymes leaders elected to key governance roles within BioMADE, a federal manufacturing innovation institute focused on bioindustrial manufacturing. These appointments highlight eXoZymes' influence in advancing cell-free biomanufacturing and shaping the industry's future direction.
- National Science Foundation (NSF) / Meta-PURE InitiativecoreSelected as core industry partner in $9.2 million NSF-funded project led by Georgia Tech aimed at advancing modular cell-free biomanufacturing. Company developing cell-free ATP-generating module and production module for santalene. Supports creation of sustainable chemical production systems.
Scale indicators8 records
Recent moves11 records
Expansion highlights6 records
eXoZymes competitors and assessment
Company assessmentDirect peers
- Codexis: Codexis engineers high-performance enzymes for pharmaceutical and sustainable chemistry applications. Most directly comparable peer given shared focus on AI/ML-guided enzyme engineering for complex molecule manufacturing and licensing-driven business model.
- DMC Biotechnologies: DMC develops cell-free biomanufacturing processes using engineered enzyme cascades to produce chemicals and specialty products. Closely matches eXoZymes' core architectural choice (cell-free over cell-based).
- Bota Bio: Bota Bio uses synthetic biology and enzyme engineering to manufacture sustainable ingredients and chemicals. Shares the AI-guided enzyme platform approach for producing high-value molecules at scale.
- Arzeda: Arzeda uses AI-driven protein design to engineer enzymes for chemical and pharmaceutical manufacturing. Comparable on the AI+enzyme engineering intersection and specialty chemical pipeline focus.
- LanzaTech: LanzaTech operates a biomanufacturing platform converting waste gases into fuels and chemicals via engineered microbes. Adjacent on biomanufacturing platform economics and sustainability-driven specialty chemicals.
Broad incumbents
- Ginkgo Bioworks: Ginkgo operates a large-scale synthetic biology platform serving pharmaceutical, industrial, and agricultural customers. While cell-based rather than cell-free, it competes for the same biomanufacturing platform customer mindshare and licensing budgets.
- Novonesis (formerly Novozymes): Novonesis is a global enzyme and microbial solutions leader across industrial, food, and health markets. Represents the incumbent enzyme platform incumbent against which any newer platform like eXoZymes must compete for commercial partnerships.
Emerging players
- Twist Bioscience: Twist Bioscience provides synthetic DNA and broader synthetic biology tools, increasingly moving into biopharma and synthetic biology-enabled product discovery. Comparable on the AI+synbio frontier and pipeline of novel molecules.
- Zymergen (Ginkgo): Now part of Ginkgo, Zymergen historically combined automation, ML, and synthetic biology for specialty chemical and materials applications. Represents the historical template of a SynBio platform company attempting specialty chemical commercialization.
- SyntheticGestalt: SyntheticGestalt applies AI to enzyme and pathway design for industrial biotechnology customers. Closely matches eXoZymes' positioning at the intersection of generative AI, enzyme engineering, and biomanufacturing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
eXoZymes social profiles
Digital presenceeXoZymes financial estimates
Financial estimateRevenue estimate
Valuation estimate
eXoZymes leadership team
Management profileNumber of profiles
Profiles7 records
eXoZymes subsidiaries and ownership
Company hierarchySubsidiaries1 record
eXoZymes funding detail
Funding detailFunding overview
Funding rounds6 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eXoZymes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eXoZymes
What does eXoZymes do?
eXoZymes operates a proprietary cell-free biomanufacturing platform that uses engineered exozymes—cell-free enzyme systems designed with the aid of its AI-driven BioClick tool—to manufacture rare, high-value natural compounds at commercial scale. The company's first commercial focus is NCT (N-trans-caffeoyltyramine), a metabolic-health compound sold through its NCTx subsidiary, with a broader pipeline spanning non-intoxicating cannabinoids, santalene, and other specialty molecules for pharmaceutical, nutraceutical, and specialty-chemical buyers.
Is eXoZymes a public or private company?
eXoZymes is a public company. It is classified as public and is currently operating.
When was eXoZymes founded?
eXoZymes was founded in 2019. It employs 11 to 50 people.
Where is eXoZymes based?
eXoZymes is headquartered in Monrovia, United States, in the North America region.
How does eXoZymes make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are product Commercialization and contract Manufacturing Services.
Who are eXoZymes's main competitors?
Direct peers on record are Codexis, DMC Biotechnologies, Bota Bio, Arzeda and LanzaTech. Broad incumbents are Ginkgo Bioworks and Novonesis (formerly Novozymes). Emerging players are Twist Bioscience, Zymergen (Ginkgo) and SyntheticGestalt.
Does eXoZymes have an API?
No public API is recorded for eXoZymes.
What industry is eXoZymes in?
eXoZymes's product category is Cell-free Biomanufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of IMAMALAB, Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids). Its NAICS code is 32519 and its SIC code is 2860.